{"id":793270,"date":"2024-12-09T06:33:49","date_gmt":"2024-12-09T11:33:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/"},"modified":"2024-12-09T06:33:49","modified_gmt":"2024-12-09T11:33:49","slug":"affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/","title":{"rendered":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MANNHEIM, Germany, Dec.  09, 2024  (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST \/ 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE<sup>\u00ae<\/sup> with atezolizumab in non-small cell lung cancer.<\/p>\n<p align=\"justify\">The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the \u201cWebcasts\u201d section on the \u201cInvestors\u201d page of the Affimed website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FcDDdPcKcISR6iYVtjAttq5hs38c6hNxVfUWnk3_bBe3MpM4T8bwi7a_knIYmbTU8q6r0l4QiD5qXGbmyuACxTc0SnNrV9r5UKX9cwSlIoAXa_qCYysiBBRyLoHEn3W8omQEjlfSgjwF9rLB-gfyjITHgrowkpcEgjttTdh14QzJzPFQhV4dO13D5sonhiRjK1XvYq4NxgeiZxAU-tW04WS9CpayJHrq3rRPpt5UYtjMGHAlgE_VA5neMlek2rcGHRO-PrKzhGWo0_QL4UlqRnLUmsYNfBqYjIlxBbF_jtxuHLu4tRr1AiROWNuhnEQH4X3pZjDu2hO16X40igbu8Hi_SMQmLpPsomMVBEENjoaWSUmBkpHBmZfNZfDpbJeiPIFss7rhvl-eBemp0ckcTLNLhrnT0Ky_0SLgrAwBImHDbaDo1eZVk79NZ-XY7b4xvn9hT2Km-wBDg1r1R1uj5KZXNCwYtASZTpWkc09vZusSfw7kTQSlH2cI9Ce009wM\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.affimed.com\/investors\/webcasts-and-corporate-presentation\/<\/a>. To access the call by phone, please use link\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FcDDdPcKcISR6iYVtjAttsY8UVYuQDJ_pf_ecKxugz1AG3hgfkNp2DNlHIL-Nx6YoWUS6aLVecNgjTIV8dCXCnoP0CkJ9sSSZrMtg10_Wjb7LN3fcSgguITIjVqh1mV1Ncd4dxNu_DuViONuEh2YCfR5e8lJGo1le7t8OfNGICJhdqSO313n6qwXlFVQKz3Srg1s1Wji1ZUxIkLfqF_xMGXb1EBRZchgNOIxR2UY0FE=\" rel=\"nofollow\" target=\"_blank\">https:\/\/register.vevent.com\/register\/BI9c2d6fa7af764cb7b550c5ce464ce5cf<\/a>, and you will be provided with dial-in details and a pin number.<\/p>\n<p align=\"justify\">\n        <strong>Note:<\/strong>\u00a0To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.<\/p>\n<p>\n        <strong>About Affimed N.V. <\/strong>\n      <\/p>\n<p>Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company\u2019s innate cell engagers (ICE<sup>\u00ae<\/sup>) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE<sup>\u00ae<\/sup> are generated on the Company\u2019s proprietary ROCK<sup>\u00ae<\/sup> platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE\u00ae molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients\u2019 lives. For more about the Company\u2019s people, pipeline and partners, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-CdmzFMAyaliVJO5KaR4uq7StjpBl2U3jdAV60PLUhPwtaVJJooQNF3JopNvx3JGYP8mQivGYpPfqBKf2TvMZQ==\" rel=\"nofollow\" target=\"_blank\">www.affimed.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Alexander Fudukidis<br \/>Director, Head of Investor Relations<br \/>E-Mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nwh-HxG6cT860X_Jqgjc_hMd51qDsglz9sFE58AQJ-j511uPEFj7zELmj6Xqs0UGuydWeZzAHO7Nd2oymPNUfIuLbIPq4TdZtuTz7Ssal7Q=\" rel=\"nofollow\" target=\"_blank\">a.fudukidis@affimed.com<\/a><br \/>Tel.: +1 (917) 436-8102<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTRiMDFiZWEtMjAzNi00N2M3LWJkNjYtZjM0YTA1ZGJhZjViLTEwMTUzMDc=\/tiny\/Affimed-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST \/ 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE\u00ae with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the \u201cWebcasts\u201d section on the \u201cInvestors\u201d page of the Affimed website at\u00a0https:\/\/www.affimed.com\/investors\/webcasts-and-corporate-presentation\/. To access the call by phone, please use link\u00a0https:\/\/register.vevent.com\/register\/BI9c2d6fa7af764cb7b550c5ce464ce5cf, and you will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793270","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST \/ 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE\u00ae with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the \u201cWebcasts\u201d section on the \u201cInvestors\u201d page of the Affimed website at\u00a0https:\/\/www.affimed.com\/investors\/webcasts-and-corporate-presentation\/. To access the call by phone, please use link\u00a0https:\/\/register.vevent.com\/register\/BI9c2d6fa7af764cb7b550c5ce464ce5cf, and you will be &hellip; Continue reading &quot;Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T11:33:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer\",\"datePublished\":\"2024-12-09T11:33:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/\"},\"wordCount\":361,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/\",\"name\":\"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\",\"datePublished\":\"2024-12-09T11:33:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk","og_description":"MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) &#8212; Affimed N.V. (Nasdaq: AFMD) (\u201cAffimed\u201d, or the \u201cCompany\u201d), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST \/ 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE\u00ae with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the \u201cWebcasts\u201d section on the \u201cInvestors\u201d page of the Affimed website at\u00a0https:\/\/www.affimed.com\/investors\/webcasts-and-corporate-presentation\/. To access the call by phone, please use link\u00a0https:\/\/register.vevent.com\/register\/BI9c2d6fa7af764cb7b550c5ce464ce5cf, and you will be &hellip; Continue reading \"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-09T11:33:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer","datePublished":"2024-12-09T11:33:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/"},"wordCount":361,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/","name":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=","datePublished":"2024-12-09T11:33:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTcxMCM2NjI3MzA5IzIwMDM3MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/affimed-to-host-investor-conference-call-highlighting-clinical-data-from-afm24-in-combination-with-atezolizumab-in-non-small-cell-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793270"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}